Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Acumen Pharmaceuticals ( (ABOS) ) has provided an announcement.
Acumen Pharmaceuticals reported third-quarter 2024 financials and outlined future milestones, with a focus on their promising Alzheimer’s treatment, sabirnetug. The company plans to complete enrollment for its Phase 2 ALTITUDE-AD study by mid-2025, and expects results from a Phase 1 study on subcutaneous administration in early 2025. Acumen, with a strong cash position of $258.9 million, is poised to sustain operations into 2027, boosting investor confidence in their innovative approach to targeting toxic amyloid beta oligomers in Alzheimer’s disease.
Learn more about ABOS stock on TipRanks’ Stock Analysis page.
